| 000 | 01354 a2200301 4500 | ||
|---|---|---|---|
| 001 | 1420044370 | ||
| 005 | 20250317100410.0 | ||
| 008 | 250312042007xx 227 eng | ||
| 020 | _a9781420044379 | ||
| 037 |
_bTaylor & Francis _cGBP 82.99 _fBB |
||
| 040 | _a01 | ||
| 041 | _aeng | ||
| 072 | 7 |
_aPS _2thema |
|
| 072 | 7 |
_aTDCW _2thema |
|
| 072 | 7 |
_aPS _2bic |
|
| 072 | 7 |
_aTDCW _2bic |
|
| 072 | 7 |
_aMED071000 _2bisac |
|
| 072 | 7 |
_aSCI013000 _2bisac |
|
| 072 | 7 |
_a615.19 _2bisac |
|
| 100 | 1 | _aDaan J. A. Crommelin | |
| 245 | 1 | 0 |
_aPharmaceutical Biotechnology _bFundamentals and Applications, Third Edition |
| 250 | _a3 | ||
| 260 |
_bCRC Press _c20071030 |
||
| 300 | _a512 p | ||
| 520 | _bCompletely revised text that reflects to emergent trends and cutting-edge advances in pharmaceutical biotechnology, this Third Edition provides a well-balanced framework for understanding every major aspect of pharmaceutical biotechnology, including drug development, production, dosage forms, administration, and therapeutic developments. New chapters cover evolving areas regarding biopharmaceuticals, including oligonucleotides, siRNA and various monoclonal antibodies, immunogenicity, gene therapy, and the regulatory issues factoring into the biopharmaceutical approval process | ||
| 700 | 1 |
_aRobert D. Sindelar _4B01 |
|
| 700 | 1 |
_aBernd Meibohm _4B01 |
|
| 999 |
_c2277 _d2277 |
||